Division of Head and Neck Oncologic Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California.
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California.
Cancer. 2021 Sep 1;127(17):3092-3106. doi: 10.1002/cncr.33611. Epub 2021 May 6.
The oncologic outcomes of surgery alone for patients with American Joint Committee on Cancer 7th edition (AJCC 7th) pN2a and pN2b human papillomavirus-associated oropharynx squamous cell carcinoma (HPV+OPSCC) are not clear.
The authors performed a 12-institution retrospective study of 344 consecutive patients with HPV+OPSCC (AJCC 7th pT0-3 N3 M0) treated with surgery alone with 6 months or more of follow-up using univariate and multivariate analyses.
The 2-year outcomes for the entire cohort were 91% (182 of 200) disease-free survival (DFS), 100% (200 of 200) disease-specific survival (DSS), and 98% (200 of 204) overall survival (OS). The 18 recurrences within 2 years were 88.9% (16 of 18) local and/or regional recurrences and 11.1% (2 of 18) distant metastases. Recurrences were not significantly associated with smoking, pT stage, or pN stage. The 16 patients with locoregional recurrences within 2 years all underwent successful salvage treatments (median follow-up after salvage: 13.1 months), 43.8% (7 of 16) of whom underwent salvage surgery alone for a 2-year overall salvage radiation need of 4.5% (9 of 200). The 2-year outcomes for the 59 evaluable patients among the 109 AJCC 7th pT0-2 N2a-N2b patients with 1 to 3 pathologic lymph nodes (LNs) were as follows: local recurrence, 3.4% (2 of 59); regional recurrence, 8.4% (5 of 59); distant metastases, 0%; DFS, 88.1% (52 of 59); DSS, 100% (59 of 59); OS, 96.7% (59 of 61); and salvage radiation, 5.1% (3 of 59).
With careful selection, surgery alone for AJCC 7th pT0-T2N0-N2b HPV+OPSCC with zero to 3 pathologic LNs without perineural invasion, extranodal extension, or positive margins results in high DFS, DSS, OS, and salvage treatment success. Because of the short-term follow-up, these data support further investigation of treatment de-escalation in this population.
对于美国癌症联合委员会第 7 版(AJCC 7 版)pN2a 和 pN2b 人乳头瘤病毒相关口咽鳞状细胞癌(HPV+OPSCC)患者,单纯手术的肿瘤学结果尚不清楚。
作者对 344 例连续接受 HPV+OPSCC(AJCC 7 版 pT0-3 N3 M0)单纯手术治疗且随访时间超过 6 个月的患者进行了 12 个机构的回顾性研究,采用单因素和多因素分析。
整个队列的 2 年结果为无疾病生存率(DFS)91%(182/200),疾病特异性生存率(DSS)100%(200/200),总生存率(OS)98%(200/204)。2 年内的 18 例复发中,88.9%(16/18)为局部和/或区域复发,11.1%(2/18)为远处转移。复发与吸烟、pT 分期或 pN 分期无显著相关性。2 年内 16 例局部区域复发患者均接受了成功的挽救治疗(挽救治疗后中位随访时间:13.1 个月),43.8%(7/16)患者仅接受挽救性手术,2 年挽救性放疗需要率为 4.5%(200 例中有 9 例)。109 例 AJCC 7 版 pT0-2N2a-N2b 患者中,1 至 3 个病理淋巴结(LN)的 59 例可评估患者的 2 年结果如下:局部复发率 3.4%(2/59);区域复发率 8.4%(5/59);远处转移率 0%;DFS 为 88.1%(52/59);DSS 为 100%(59/59);OS 为 96.7%(59/61);挽救性放疗率为 5.1%(3/59)。
对于 AJCC 7 版 pT0-T2N0-N2b 伴 0 至 3 个无神经周围侵犯、结外扩展或阳性切缘的 HPV+OPSCC 患者,经仔细选择后,单纯手术治疗可获得较高的 DFS、DSS、OS 和挽救治疗成功率。由于随访时间较短,这些数据支持在该人群中进一步探索治疗降级。